British journal of cancer · 1996

A prognostic index for multiple myeloma.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Grignani G, Gobbi PG, Formisano R, Pieresca C, Ucci G, Brugnatelli S, Riccardi A, Ascari E

Аннотация

The current prognostic systems have failed to identify multiple myeloma (MM) patients who require aggressive therapy. These staging systems do not reliably distinguish patients with different prognoses. This paper explores the possibility of improving the prognostic forecast in MM by considering some clinical characteristics at diagnosis together with response to first-line chemotherapy. A total of 231 patients were prospectively randomised in a multicentre trial to no therapy vs melphalan + prednisone (MP) for stage I, MP in stage II, and MP vs peptichemio, vincristine and prednisone for stage III. The clinical features of these groups were evaluated for prognostic variables predictive of overall survival by means of univariate and multivariate analysis. The independently significant variables were incorporated into a model that identified three groups of patients with different risks of death and different overall survival. Three variables retained statistical significance: the staging system proposed by the British Medical Research Council, a composite parameter integrating the percentage of bone marrow plasma cells with cytological features of the infiltrating elements (plasma cell vs plasmablast), and response to 6 months of first-line chemotherapy. These three variables led the proposal of a scoring system able to identify three different risk classes (with median overall survival of 52, 28 and 13 months respectively) and to estimate individual patient prognosis more flexibly. The proposed risk classes, drawn from both diagnostic and therapeutic parameters, are thought to be a clinical and investigational instrument for separating MM patients into comparable groups, for selecting the best available therapy and for evaluating response with respect to the disease of each new patient.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Alexanian R. Dimopoulos M. Smith T. Delasalle K. Barlogie B. Champlin R. Limited value of myeloablative therapy for late multiple myeloma. 83 2 15 1 1994 512 516 Blood 7904486

Alexanian R. Dimopoulos M. The treatment of multiple myeloma. 330 7 17 2 1994 484 489 N Engl J Med 8289856 10.1056/NEJM199402173300709

Attal M. Huguet F. Schlaifer D. Payen C. Laroche M. Fournie B. Mazieres B. Pris J. Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. 79 5 1 3 1992 1130 1136 Blood 1536941

Bartl R. Frisch B. Burkhardt R. Fateh-Moghadam A. Mahl G. Gierster P. Sund M. Kettner G. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. 51 3 7 1982 361 375 Br J Haematol 7104223 10.1111/j.1365-2141.1982.tb02791.x

Bartl R. Histologic classification and staging of multiple myeloma. 6 2 Apr-Jun 1988 107 113 Hematol Oncol 3391529 10.1002/hon.2900060209

Bataille R. Boccadoro M. Klein B. Durie B. Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. 80 3 1 8 1992 733 737 Blood 1638024

Bugliosi R. Tribalto M. Avvisati G. Boccardoro M. de Martinis C. Friera R. Mandelli F. Pileri A. Papa G. Classification of patients affected by multiple myeloma using a neural network software. 52 3 3 1994 182 183 Eur J Haematol 8168599 10.1111/j.1600-0609.1994.tb01312.x

Caligaris-Cappio F. Bergui L. Tesio L. Pizzolo G. Malavasi F. Chilosi M. Campana D. van Camp B. Janossy G. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. 76 3 9 1985 1243 1251 J Clin Invest PMC424031 2931452 10.1172/JCI112080

Caligaris-Cappio F. Gregoretti M. G. Ghia P. Bergui L. In vitro growth of human multiple myeloma: implications for biology and therapy. 6 2 4 1992 257 271 Hematol Oncol Clin North Am 1582973

Carter A. Hocherman I. Linn S. Cohen Y. Tatarsky I. Prognostic significance of plasma cell morphology in multiple myeloma. 60 5 1 9 1987 1060 1065 Cancer 3607725 10.1002/1097-0142(19870901)60:5<1060::aid-cncr2820600522>3.0.co;2-3

Cohen H. J. Bartolucci A. A. Forman W. B. Silberman H. R. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 4 6 6 1986 888 899 J Clin Oncol 3519879 10.1200/JCO.1986.4.6.888

Cooper M. R. McIntyre O. R. Propert K. J. Kochwa S. Anderson K. Coleman M. Kyle R. A. Prager D. Rafla S. Zimmer B. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. 4 9 9 1986 1331 1339 J Clin Oncol 3528403 10.1200/JCO.1986.4.9.1331

Cunningham D. Paz-Ares L. Milan S. Powles R. Nicolson M. Hickish T. Selby P. Treleavan J. Viner C. Malpas J. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. 12 4 4 1994 759 763 J Clin Oncol 8151319 10.1200/JCO.1994.12.4.759

Dimopoulos M. A. Alexanian R. Przepiorka D. Hester J. Andersson B. Giralt S. Mehra R. van Besien K. Delasalle K. B. Reading C. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. 82 8 15 10 1993 2324 2328 Blood 8104539

Drewinko B. Alexanian R. Boyer H. Barlogie B. Rubinow S. I. The growth fraction of human myeloma cells. 57 2 2 1981 333 338 Blood 7448427

Durie B. G. Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. 36 3 9 1975 842 854 Cancer 1182674 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u

Epstein J. Xiao H. Q. He X. Y. Markers of multiple hematopoietic-cell lineages in multiple myeloma. 322 10 8 3 1990 664 668 N Engl J Med 2137556 10.1056/NEJM199003083221005

Fermand J. P. Chevret S. Ravaud P. Divine M. Leblond V. Dreyfus F. Mariette X. Brouet J. C. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. 82 7 1 10 1993 2005 2009 Blood 8104534

Fritz E. Ludwig H. Kundi M. Prognostic relevance of cellular morphology in multiple myeloma. 63 5 5 1984 1072 1079 Blood 6713092

Gobbi P. G. Bertoloni D. Grignani G. Pieresca C. Rossi A. Rutigliano L. Merlini G. Riccardi A. Ascari E. A plea to overcome the concept of "staging" and related inadequacy in multiple myeloma. 46 3 3 1991 177 181 Eur J Haematol 2009950 10.1111/j.1600-0609.1991.tb01273.x

Goldie J. H. Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. 63 11-12 Nov-Dec 1979 1727 1733 Cancer Treat Rep 526911

Gore M. E. Selby P. J. Viner C. Clark P. I. Meldrum M. Millar B. Bell J. Maitland J. A. Milan S. Judson I. R. Intensive treatment of multiple myeloma and criteria for complete remission. 2 8668 14 10 1989 879 882 Lancet 2571812 10.1016/s0140-6736(89)91548-1

Gregory W. M. Richards M. A. Malpas J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. 10 2 2 1992 334 342 J Clin Oncol 1531068 10.1200/JCO.1992.10.2.334

Greipp P. R. Advances in the diagnosis and management of myeloma. 29 3 Suppl 2 7 1992 24 45 Semin Hematol 1509293

Greipp P. R. Raymond N. M. Kyle R. A. O'Fallon W. M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. 65 2 2 1985 305 310 Blood 3967084

Guillemin F. Guerci A. P. Feugier P. Péré P. Pourel J. Guerci O. Development of a criterion for response to therapy at 6 months in multiple myeloma. 55 2 8 1995 110 116 Eur J Haematol 7628585 10.1111/j.1600-0609.1995.tb01819.x

Harousseau J. L. Milpied N. Laporte J. P. Collombat P. Facon T. Tigaud J. D. Casassus P. Guilhot F. Ifrah N. Gandhour C. Double-intensive therapy in high-risk multiple myeloma. 79 11 1 6 1992 2827 2833 Blood 1350228

Jagannath S. Barlogie B. Dicke K. Alexanian R. Zagars G. Cheson B. Lemaistre F. C. Smallwood L. Pruitt K. Dixon D. O. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. 76 9 1 11 1990 1860 1866 Blood 2224133

Johnson P. W. Selby P. J. The treatment of multiple myeloma--an important MRC trial. 70 5 11 1994 781 785 Br J Cancer PMC2033545 7947081 10.1038/bjc.1994.399

Kotasek D. Shepherd K. M. Sage R. E. Dale B. M. Norman J. E. Charles P. Gregg A. Pillow A. Bolton A. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. 9 1 1 1992 11 17 Bone Marrow Transplant 1347478

Kubagawa H. Vogler L. B. Capra J. D. Conrad M. E. Lawton A. R. Cooper M. D. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. 150 4 1 10 1979 792 807 J Exp Med PMC2185666 92518 10.1084/jem.150.4.792

Kyle R. A. Newer approaches to the management of multiple myeloma. 72 11 Suppl 1 12 1993 3489 3494 Cancer 8242581 10.1002/1097-0142(19931201)72:11+<3489::aid-cncr2820721616>3.0.co;2-3

MacLennan I. C. Kelly K. Crockson R. A. Cooper E. H. Cuzick J. Chapman C. Results of the MRC myelomatosis trials for patients entered since 1980. 6 2 Apr-Jun 1988 145 158 Hematol Oncol 3292372 10.1002/hon.2900060215

Merlini G. Waldenström J. G. Jayakar S. D. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. 55 6 6 1980 1011 1019 Blood 7378577

Moro M. J. Portero J. A. Gascón A. Hernández J. M. Ortega F. Jiménez R. Guerras L. Martínez M. Casanova F. Sanz M. A. Utilidad del examen de la morfología de la célula plasmática en el estudio del mieloma múltiple. 37 3 6 1992 175 179 Sangre (Barc) 1440094

Niesvizky R. Siegel D. Michaeli J. Biology and treatment of multiple myeloma. 7 1 3 1993 24 33 Blood Rev 8467229 10.1016/0268-960x(93)90021-u

Pasqualetti P. Casale R. Collacciani A. Abruzzo B. P. Colantonio D. Multiple myeloma: relationship between survival and cellular morphology. 33 2 2 1990 145 147 Am J Hematol 2301373 10.1002/ajh.2830330214

Paule B. Quillard J. Bisson M. Kahn M. F. Massias P. Prognostic significance of plasma cell morphology in multiple myeloma. 30 4 1988 209 212 Nouv Rev Fr Hematol 3194186

Pavlovsky S. Corrado C. Santarelli M. T. Saslavsky J. Cavagnaro F. Palau M. de Tezanos Pinto M. Huberman A. Lein J. M. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study. 6 5 5 1988 769 775 J Clin Oncol 3284974 10.1200/JCO.1988.6.5.769

Pilarski L. M. Mant M. J. Ruether B. A. Pre-B cells in peripheral blood of multiple myeloma patients. 66 2 8 1985 416 422 Blood 3893567

Riccardi A. Gobbi P. G. Ucci G. Bertoloni D. Luoni R. Rutigliano L. Ascari E. Changing clinical presentation of multiple myeloma. 27 11 1991 1401 1405 Eur J Cancer 1835856 10.1016/0277-5379(91)90020-e

Riccardi A. Merlini G. Montecucco C. Danova M. Ucci G. Cassano E. Ascari E. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. 22 7 7 1986 787 791 Eur J Cancer Clin Oncol 3770037 10.1016/0277-5379(86)90364-0

San Miguel J. F. Moro M. J. Gonzalez M. Plasmablastic multiple myeloma: an immunologically different subtype. 66 2 6 1987 275 275 Br J Haematol 3606964 10.1111/j.1365-2141.1987.tb01312.x

Sukpanichnant S. Cousar J. B. Leelasiri A. Graber S. E. Greer J. P. Collins R. D. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. 25 3 3 1994 308 318 Hum Pathol 8150462 10.1016/0046-8177(94)90204-6

Tribalto M. Amadori S. Cantonetti M. Franchi A. Papa G. Pileri A. Boccadoro M. Dammacco F. Vacca A. Centurioni R. Treatment of multiple myeloma: a randomized study of three different regimens. 9 8 1985 1043 1049 Leuk Res 3900591 10.1016/0145-2126(85)90075-x

A prognostic index for multiple myeloma.

Ошибки и ограничения

Аннотация